These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 28604720)

  • 21. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
    Deveuve Q; Lajoie L; Barrault B; Thibault G
    Front Immunol; 2020; 11():168. PubMed ID: 32117299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.
    Spirig R; Campbell IK; Koernig S; Chen CG; Lewis BJB; Butcher R; Muir I; Taylor S; Chia J; Leong D; Simmonds J; Scotney P; Schmidt P; Fabri L; Hofmann A; Jordi M; Spycher MO; Cattepoel S; Brasseit J; Panousis C; Rowe T; Branch DR; Baz Morelli A; Käsermann F; Zuercher AW
    J Immunol; 2018 Apr; 200(8):2542-2553. PubMed ID: 29531170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
    Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
    MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.
    Boesch AW; Miles AR; Chan YN; Osei-Owusu NY; Ackerman ME
    MAbs; 2017 Apr; 9(3):455-465. PubMed ID: 28055295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice.
    Lo M; Kim HS; Tong RK; Bainbridge TW; Vernes JM; Zhang Y; Lin YL; Chung S; Dennis MS; Zuchero YJ; Watts RJ; Couch JA; Meng YG; Atwal JK; Brezski RJ; Spiess C; Ernst JA
    J Biol Chem; 2017 Mar; 292(9):3900-3908. PubMed ID: 28077575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isotype and glycoform selection for antibody therapeutics.
    Jefferis R
    Arch Biochem Biophys; 2012 Oct; 526(2):159-66. PubMed ID: 22465822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.
    Fox JM; Roy V; Gunn BM; Huang L; Edeling MA; Mack M; Fremont DH; Doranz BJ; Johnson S; Alter G; Diamond MS
    Sci Immunol; 2019 Feb; 4(32):. PubMed ID: 30796092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
    Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
    J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease.
    Zhang X; Olsen HS; Chen S; So E; Zhou H; Burch E; Mérigeon EY; Block DS; Strome SE
    J Immunol; 2016 Feb; 196(3):1165-76. PubMed ID: 26695368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc.
    Idusogie EE; Presta LG; Gazzano-Santoro H; Totpal K; Wong PY; Ultsch M; Meng YG; Mulkerrin MG
    J Immunol; 2000 Apr; 164(8):4178-84. PubMed ID: 10754313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.
    Wang G; de Jong RN; van den Bremer ET; Beurskens FJ; Labrijn AF; Ugurlar D; Gros P; Schuurman J; Parren PW; Heck AJ
    Mol Cell; 2016 Jul; 63(1):135-45. PubMed ID: 27320199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
    Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
    MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
    Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
    Front Immunol; 2018; 9():958. PubMed ID: 29867943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes.
    Bailey EM; Choudhury A; Vuppula H; Ortiz DF; Schaeck J; Manning AM; Bosques CJ; Hoppe AD
    Front Immunol; 2020; 11():617767. PubMed ID: 33679705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
    Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
    Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
    Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
    Pereira NA; Chan KF; Lin PC; Song Z
    MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength.
    Bondza S; Marosan A; Kara S; Lösing J; Peipp M; Nimmerjahn F; Buijs J; Lux A
    Front Immunol; 2020; 11():609941. PubMed ID: 33505398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.
    Kline JB; Fernando S; Ross EN; Grasso L; Nicolaides NC
    Eur J Immunol; 2018 Nov; 48(11):1872-1882. PubMed ID: 30144039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y; Yamada T; Mori K; Okazaki A; Inoue M; Kitajima-Miyama K; Kuni-Kamochi R; Nakano R; Yano K; Kakita S; Shitara K; Satoh M
    Glycobiology; 2007 Jan; 17(1):104-18. PubMed ID: 17012310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.